The company's principal activity is to develop novel drugs. The drugs provide pain relief and reduced tolerance and physical dependence or addiction potential compared to existing opioid painkillers. The drugs combine very low doses of opioid antagonists with standard opioid painkillers. The company has three proprietary drug candidates in clinical development: oxytrextm, remoxytm and pti-901. Oxytrex and pti-901 are in phase iii clinical trials and remoxy is in phase i clinical trials in the United Kingdom. These drugs are awaiting approval from the food and drug administration. The company is the development stage.
